These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25432176)

  • 1. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
    Kolev VN; Wright QG; Vidal CM; Ring JE; Shapiro IM; Ricono J; Weaver DT; Padval MV; Pachter JA; Xu Q
    Cancer Res; 2015 Jan; 75(2):446-55. PubMed ID: 25432176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
    Zhou H; Yu C; Kong L; Xu X; Yan J; Li Y; An T; Gong L; Gong Y; Zhu H; Zhang H; Yang X; Li Y
    Oncogene; 2019 May; 38(18):3371-3386. PubMed ID: 30635656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
    Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
    Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
    Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
    J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.
    Karthik GM; Ma R; Lövrot J; Kis LL; Lindh C; Blomquist L; Fredriksson I; Bergh J; Hartman J
    Cancer Lett; 2015 Oct; 367(1):76-87. PubMed ID: 26208432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
    Ning C; Liang M; Liu S; Wang G; Edwards H; Xia Y; Polin L; Dyson G; Taub JW; Mohammad RM; Azmi AS; Zhao L; Ge Y
    Oncotarget; 2017 Jul; 8(27):44295-44311. PubMed ID: 28574828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
    Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
    J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
    Hart S; Novotny-Diermayr V; Goh KC; Williams M; Tan YC; Ong LC; Cheong A; Ng BK; Amalini C; Madan B; Nagaraj H; Jayaraman R; Pasha KM; Ethirajulu K; Chng WJ; Mustafa N; Goh BC; Benes C; McDermott U; Garnett M; Dymock B; Wood JM
    Mol Cancer Ther; 2013 Feb; 12(2):151-61. PubMed ID: 23270925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
    Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
    PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
    Hong Z; Xiao M; Yang Y; Han Z; Cao Y; Li C; Wu Y; Gong Q; Zhou X; Xu D; Meng L; Ma D; Zhou J
    Carcinogenesis; 2011 Oct; 32(10):1550-8. PubMed ID: 21803735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
    Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
    PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition.
    Fourneaux B; Bourdon A; Dadone B; Lucchesi C; Daigle SR; Richard E; Laroche-Clary A; Le Loarer F; Italiano A
    J Hematol Oncol; 2019 Jan; 12(1):11. PubMed ID: 30683135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
    Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Gazi M; Moharram SA; Marhäll A; Kazi JU
    Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.
    Britschgi A; Andraos R; Brinkhaus H; Klebba I; Romanet V; Müller U; Murakami M; Radimerski T; Bentires-Alj M
    Cancer Cell; 2012 Dec; 22(6):796-811. PubMed ID: 23238015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
    Herrera VA; Zeindl-Eberhart E; Jung A; Huber RM; Bergner A
    Anticancer Res; 2011 Mar; 31(3):849-54. PubMed ID: 21498705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.